Regulation of Small-Molecule Drugs Versus Biologicals Versus Biotech Products

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 1373-1390

  Castillo, María de los Angeles Cortés ^a   di Fabio, José Luis ^a  

^a PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

Drugs versus biologicals versus biotech products; Main regulatory agencies; WHO global role in drugs and biologicals regulation

Indexed keywords

EID: 84889808086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch12a     Document Type: Chapter

References (22)

1. Chabra R, Kremzner M E, Killany B J (2005). FDA policy on unappproved drug products: Past, present and future. Ann. Pharmacother. 39:1260-1264.
2. Bren L (2006). The road to the biotech revolution: Highligths of 100 years of biologics regulation. FDA Consumer Mag. Centen. Edn. 1-7.
3. Offit PA (2005). The Cutter Incident. Yale University Press, New Haven, CT, pp. 83-131.
4. Baylor N W, Midthun K (2004). Regulation and testing of vaccines. In B A Plotkin, W A Orenstein (eds.), Vaccines, 4th ed.: Saunders, Philadelphia, PA, pp. 1539-1555.
5. Structure of ICH. Available: www.ich.org/cache/html/355-272-1.html.
6. WHO/Drug regulation. Available: www.who.int/medicines/areas/quality_safety/.
7. Ratanawijitrasin S, Wondemagegnehu E (2002). Effective drug regulation. A multicountry study. WHO. pp. 7-10.
8. Ng R (2004). Drugs. From Discovery to Approval. John Wiley and Sons, Inc., New York, pp. 51, 176-178, 212.
9. World Health Organization, Geneva (1999). Regulation of vaccines: Building on existing drug regulatory authorities. WHO/V&B/99. pp. 1-28.
10. Wadman M (2006). London's disastrous drug trial has serious side effects for research. Nature. 440:388-389.
11. Walsh G (2003). Biopharmaceutical benchmarks. Nat. Biotechnol. 21:865-870.
12. Hopkin M (2006). Can super-antibody drugs be tamed? Nature. 440:855-859.
13. Goldstein D A, Thomas J A (2004). Biopharmaceuticals derived from genetically modified plants. QJ Med. 97:705-716.
14. Ma J K, Barros E, Bock R, et al. (2005). Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. The European Union Framework 6 Pharma-Planta Consortium. EMBO Reports. 6(7):593-599.
15. Walsh G (2000). Biopharmaceuticals benchmarcks. Nat. Biotechnol. 18:831-833.
16. Wayne A, Ray W A, Stein M (2006). Reform on drug regulation-beyond and independiente drug safety board. N. Engl. J. Med. 354:194-200.
17. About the EMEA-Structure. Available: www.emea.eu.int.
18. Awang D C M Z B C (2003). ASEAN Initiatives toward pharmaceutical regulatory harmonization. Drug Info. J. 37:55-58.
19. Heidenreich K (2006). Dialogue between companies and the EMEA regarding the centralized procedure from an industry's point of view. Drug Info. J. 40:15-21.
20. Fontanarosa P B, Rennie D, De Angelis C D (2004). Post marketing surveillance-lack of vigilance, lack of trust. JAMA. 292(21):2647-2650.
21. Lexchin J (2006). Is there still a role for spontanous reporting of adverse drug reactions? CMAJ. J. 174:191-192.
22. Nutt D J (2006). Informed consent-a new approach to drug regulation? J. Psychopharmacol. 20:3-4.